MHRA approves Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of advanced HER2-positive breast cancer

The authorisation is based on results from HER2CLIMB trial that enrolled 612 patients with HER2-positive unresectable locally advanced or metastatic breast cancer who had previously received separately or in combination– trastuzumab, pertuzumab and ado-trastuzumab emtansine.

Source:

PharmaTimes